Explain It to Me Please

Intuitive Surgical operates as the dominant pioneer in the robotic-assisted surgery (RAS) industry. The company's economic moat is characterized by exceptionally high switching costs, a vast installed base of over 13,200 systems, and a highly integrated ecosystem of recurring revenue streams3. The core business operates through three primary segments: Systems (capital equipment), Instruments and Accessories (I&A - recurring consumables), and Services (recurring maintenance and analytics).

The deliberate transition from a pure capital-sales model to an operating-lease and recurring-revenue model has structurally fortified the quality of Intuitive’s earnings. As of Q3 2026, recurring revenue constituted 84% of total sales7. The introduction of the da Vinci 5 system serves as a major catalyst. Featuring 10,000x the computing power of its predecessor, the da Vinci 5 integrates proprietary Force Feedback (FFB) technology6. Peer-reviewed clinical data indicates that FFB reduces the average force applied to tissues during surgery, minimizing trauma and shortening recovery times, which reinforces the clinical value proposition against traditional laparoscopy

Despite the expiration of foundational patents that originally insulated the da Vinci architecture, Intuitive has maintained its moat through iterative innovation, aggressive intellectual property defense, a vast network of trained surgeons (over 18,000 trained on da Vinci 5 alone since launch), and substantial regulatory barriers3. The primary fundamental headwind facing the firm is the rapid adoption of GLP-1 receptor agonists (e.g., semaglutide), which have caused a deceleration in bariatric surgery volumes18. However, the overall impact is partially offset by double-digit growth in general surgery, oncology, and the rapid expansion of the Ion endoluminal system for lung biopsies, which saw procedure growth of 31% in the latest quarter

Fundamental and Business Analysis

RTX Corporation operates as a premier global aerospace and defense conglomerate, formed by the 2020 merger of Raytheon Company and United Technologies Corporation's aerospace businesses. The company is structured into three principal segments: Collins Aerospace, Pratt & Whitney, and Raytheon

Collins Aerospace is a leading provider of technologically advanced aerospace and defense products. Its portfolio includes aerostructures, avionics, interiors, mechanical systems, and mission systems. The segment benefits from highly recurring commercial aftermarket revenues. In Q3 2026, Collins delivered adjusted sales of $8.4 billion, up 10% year-over-year, driven heavily by a 23% increase in commercial original equipment (OE) and a 9% increase in commercial aftermarket sales14. The ongoing recovery in global widebody and narrowbody flight hours serves as a structural tailwind for this segment.

Pratt & Whitney (P&W) designs, manufactures, and services aircraft engines and auxiliary power systems. P&W's flagship product is the PW1000G Geared Turbofan (GTF) engine, which powers the Airbus A320neo, Airbus A220, and Embraer E-Jets E216. While the GTF delivers superior fuel efficiency, it has been plagued by a rare powder-metal contamination issue that originated between 2015 and 2021, leading to accelerated inspections and a peak grounding of approximately 650 aircraft17. RTX recognized a massive $3 billion charge in Q3 2023 to account for airline compensation and repair costs18. However, as of Q3 2026, the segment is recovering; MRO (Maintenance, Repair, and Overhaul) output for the PW1100G increased by 35% year-over-year, and commercial aftermarket sales surged 21%19. The segment also produces the F135 engine for the F-35 Lightning II, which is undergoing an Engine Core Upgrade (ECU) to support future Block 4 capabilities.

Raytheon focuses on offensive and defensive threat detection, interceptors, and space systems. Key programs include the Patriot missile defense system, AMRAAM, Tomahawk, and the Lower Tier Air and Missile Defense Sensor (LTAMDS)20. Q3 2026 sales for Raytheon reached $8.0 billion, up 14% year-over-year15. The segment is currently benefiting from heightened global defense spending and the replenishment of munitions utilized in recent geopolitical conflicts.

Industry Trends and Moat: The aerospace and defense industry is characterized by steep barriers to entry, highly consolidated supply chains, massive capital intensity, and extensive regulatory hurdles. These factors constitute a "wide economic moat" for RTX. The company's competitive advantage is anchored in its massive installed base—for instance, over 71,000 P&W engines worldwide—which guarantees decades of high-margin aftermarket service revenues20. Furthermore, RTX holds sole-provider status on critical defense infrastructure, such as the U.S. Navy's Cooperative Engagement Capability (CEC), which it has supplied since 1985.

Incorporated on October 28, 2013, as a Swiss stock corporation (Aktiengesellschaft) under the name Inception Genomics AG (renamed CRISPR Therapeutics AG on April 28, 2014) and headquartered at Baarerstrasse 14 in Zug, Switzerland, with primary research and development operations in Boston and Framingham, Massachusetts, CRISPR Therapeutics AG is a commercial-stage biotechnology company developing transformative gene-based medicines21. Although domiciled in Switzerland, the company files domestic U.S. GAAP periodic reports (Forms 10-K, 10-Q, and 8-K) with the U.S. Securities and Exchange Commission as a well-known seasoned issuer

The company's foundational technology is built upon Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a bacterial adaptive immune mechanism programmed to cleave double-stranded genomic DNA at precise target sequences25. Co-founder Dr. Emmanuelle Charpentier, alongside Dr. Jennifer Doudna, was awarded the 2020 Nobel Prize in Chemistry for elucidating the CRISPR/Cas9 gene-editing mechanism12. CRISPR Therapeutics holds exclusive therapeutic rights to Dr. Charpentier's foundational patent estate and has expanded its technological architecture to include next-generation base and gene-correction platforms (CRISPR-X and SyNTase), lipid nanoparticle (LNP) in vivo delivery vehicles, allogeneic cell engineering, and small interfering RNA (siRNA) therapeutics2

Anton Korinek, Charles I. Jones, Szymon Sacher, Tess Cotter, and Peter McCrory

The Anthropic Institute Working Paper No. 2026-02

September 2026

This is an AI generated review of a paper by economists from Anthropic that presents a framework for assessing the economic consequences of AI between 2026 and 2030. In the model, AI automates a growing share of cognitive work, raising productivity and displacing workers whomust search for jobs in other occupations. The model maps future paths of AI capabilities into implied paths for GDP, the labor share, wages, labor reallocation, and unemployment.

They illustrate the framework by considering three scenarios: modest, substantial, and extreme. Under modest change, AI adds less than half a point to GDP growth by 2030 and raises unemployment by a tenth of a point. In the extreme change scenario, AI has transformative effects, with AI performing almost half of today’s cognitive work by 2030. GDP growth then rises to 15 percent per year, the labor share of income falls from 60 to 45 percent, and nearly one in five cognitive workers is unemployed. We also surveyed US adults about their expectations for AI.

Views vary widely, but the median respondent’s answers are consistent with our substantial change scenario in which, by 2030, GDP rises by 8 percent and cognitive employment declines by 4 percent. The model offers a structured way to compare possibilities for our economic future under different expectations about AI.

Weekly Market and Portfolio News

Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices utilized across a broad spectrum of interventional medical specialties, distributing products to hospitals, clinics, and outpatient centers in 127 countries via direct sales forces and distributor networks1. Management operates the enterprise around five core strategic imperatives: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth, and Develop Key Capabilities28. In the fourth quarter of 2025, Boston Scientific executed an organizational realignment that combined its legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular segment, operating alongside its MedSurg segment1. In the second quarter of 2026, Cardiovascular generated 67% of total net sales ($1,818 million)9.

The Cardiovascular segment accounted for 66% of FY 2025 revenue and 67% of Q2 2026 revenue. Operations in this segment span five primary franchises:

The MedSurg segment accounted for 34% of FY 2025 revenue and 33% of Q2 2026 revenue across three specialized franchises:

Neuromodulation ($341 million in Q2 2026): Offers WaveWriter Spinal Cord Stimulator (SCS) Systems with FAST Therapy (expanded FDA approval in Q1 2024 for non-surgical chronic low back and leg pain), the Intracept Intraosseous Nerve Ablation System for vertebrogenic back pain, G4 Radiofrequency Ablation (RFA) generators, peripheral nerve stimulation via Nalu Medical, and Vercise Genus Deep Brain Stimulation (DBS) systems for Parkinson's disease9.

Shopify Inc. provides cloud-based, multi-channel commerce infrastructure designed to allow merchants of all sizes—from first-time entrepreneurs to global enterprise brands—to start, scale, market, and operate retail businesses across web, mobile, social media, marketplaces, brick-and-mortar point-of-sale (POS), and business-to-business (B2B) channels19. The platform powers over 6.5 million active storefronts across more than 175 countries, with a highly diversified merchant base in which no single merchant has ever accounted for more than 5% of total consolidated revenue in a single reporting period20.

Shopify generates revenue through two synergistic operating components: Subscription Solutions and Merchant Solutions19. Subscription Solutions accounted for 22.4% of Q2 2026 revenue and 23.8% of FY2025 revenue, generating recurring revenue through monthly and annual platform subscription plans (Basic, Grow/Shopify, Advanced, and enterprise-grade Shopify Plus), POS Pro subscriptions, variable platform fees, and revenue-sharing arrangements from the sale of themes, domain names, and more than 21,000 third-party applications in the Shopify App Store1. Subscription Solutions serves as the high-margin customer acquisition funnel for the enterprise, consistently delivering gross margins near 80%, specifically 79.7% in Q2 2026 and 81.1% in FY20251.

Merchant Solutions accounted for 77.6% of Q2 2026 revenue and 76.2% of FY2025 revenue, generating usage-based, transaction-linked revenue that scales directly with merchant Gross Merchandise Volume (GMV)1. The primary revenue driver within this segment is Shopify Payments, a fully integrated payment processing service that reached 68% GMV penetration in Q2 2026, up from 65% in Q3 2025 and 67% in Q1 202622. Additional Merchant Solutions offerings include Shop Pay, an accelerated consumer checkout network achieving approximately 72.5% checkout completion rates versus an industry average of roughly 62.6%23; Shopify Capital, which provides working capital loans and merchant cash advances and stood at $2,184 million net on the balance sheet as of June 30, 20261; Shopify Markets, which facilitates cross-border duties, tax calculation, and localization powered in part by Global-e16; Shopify Shipping; POS hardware sales; and partner referral fees25. Because payment processing incurs direct interchange and card network assessment fees, Merchant Solutions carries a lower structural gross margin of 38.4% in Q2 2026 and 37.7% in FY20251.

261012 Weekly Market and Portfolio News

Weekly Market and Porfolio News

Eli Lilly operates predominantly as a single-segment human pharmaceutical manufacturer, deriving its revenue across four primary therapeutic domains: Cardiometabolic Health, Oncology, Immunology, and Neuroscience12. The structural narrative defining Eli Lilly’s fundamental performance over the trailing five years is the unprecedented volumetric and pricing expansion of its incretin analog portfolio.

The total addressable market (TAM) for obesity and type 2 diabetes is estimated to exceed $100 billion globally by 2030, driven by shifting treatment paradigms that prioritize weight reduction as a primary intervention for downstream cardiovascular and metabolic disorders14. Eli Lilly's economic moat is secured by stringent patent protections, high barriers to entry regarding large-scale sterile peptide manufacturing, and complex global distribution networks. The company's strategic pivot toward multi-receptor agonism—specifically targeting GLP-1, GIP, and glucagon receptors simultaneously—has established a new efficacy frontier that generic manufacturers and smaller biotechnology firms lack the capital and infrastructure to replicate

Sales trends from 2021 through 2025 exhibit a non-linear acceleration. The commercial scaling of Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) triggered compounding top-line growth. Gross margins have consistently expanded as a function of product mix, with higher-margin incretin therapies comprising a supermajority of net revenue.

By 2025, the company's gross margin expanded to 83.6%, reflecting manufacturing efficiencies and high realized prices despite rebate pressures18. The primary risk to the moat relies on impending patent cliffs for legacy products. Trulicity, Verzenio, Jardiance, and Taltz are approaching the end of their respective data exclusivity and patent protection periods20. However, the analysis indicates that the pipeline—anchored by retatrutide, orforglipron, and donanemab (Kisunla)—provides sufficient revenue replacement velocity to offset generic erosion